GlobeNewsWire · CELC · October 23, 2026

Celcuity Presents Updated Data from a Phase 1b/2 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration-Resistant Prostate Cancer at the ESMO Congress 2026

Get the app for more

Explore stock news, insights and company research.